Houston biopharma company CoRegen said it has received US Food and Drug Administration clearance to begin a Phase I/II trial of CRG-150, an adoptive cell therapy targeting steroid receptor coactivator ...
The gene therapy for multiple sulfatase deficiency was one of the preclinical programs the Bespoke Gene Therapy Consortium selected for its pilot.
Spur Therapeutics on Tuesday said it has treated the first Gaucher disease patient with its investigational gene therapy, FLT201 (avigbagene parvec), in a pivotal trial. In the Phase III GALILEO-3 ...
The firm said it will use the funds to advance its KRAS-targeted cancer vaccine ELI-002 7P in KRAS-driven pancreatic cancer.
The British company is developing two ADCs against B7-H3 and HER2 using a novel payload it is betting can overcome resistance to other ADCs.
The firm recently advanced its first candidate into clinical testing, evaluating STX-1150 as a treatment for hypercholesterolemia.
NEW YORK – The US Food and Drug Administration has accepted two supplemental new drug applications (sNDAs) seeking to convert accelerated approvals for two of Sarepta Therapeutics' Duchenne muscular ...
During its research day, the firm discussed a cell therapy effort in lupus, dubbed "007," and an AI platform for gleaning ...
Three cases suggest some clinicians lack understanding of relatively common autosomal recessive disorders and are ...
In a Phase III trial, divarasib bested first-generation drugs Lumakras and Krazati, which the firm said could make it a new standard of care in KRAS G12C-mutated NSCLC.
Vertex Pharmaceuticals and CRISPR Therapeutics' gene-editing drug is the only sickle cell disease gene therapy on the market for young children.
The last recurrence in the long-term study occurred at 5.4 years, leading researchers to be more comfortable using the term ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results